IO Biotech Reveals 5-Year Clinical Trial Outcomes in Nature
IO Biotech’s peptide vaccine IO102-IO103 combined with nivolumab delivered a median progression-free survival of 25.5 months, a median duration...
Imviva Doses First Patient in CAR-T Cell Therapy Trial
A first U.S. patient treated with Imviva’s allogeneic anti‑CD7 CAR‑T, CTD402, in the TENACITY‑01 study achieved a complete remission...
Secura Bio Highlights Progress in Phase 3 Terzo Study Update
Secura Bio has randomized 35 of 124 planned patients and activated 43 of 45 sites across ten European countries...
Biosplice Doses First Patient in Ovarian Cancer Trial
Biosplice Therapeutics has initiated dosing in an investigator-initiated Phase 1 study testing cirtuvivint, a pan-CLK/DYRK inhibitor, in combination with...
Neonc Technologies Announces Updated Clinical Trial Results
In an expanded 25-patient Phase 1/2a plus compassionate-use cohort of recurrent WHO Grade III/IV IDH1-mutant astrocytoma, intranasal NEO100 produced...
Elraglusib Shows Promising Results in Phase II Cancer Study
Median overall survival reached 18.6 months across 32 patients with metastatic salivary gland cancers treated with elraglusib plus carboplatin...
Medicus Pharma Completes Enrolment for Phase 2 BCC Study
Interim data from Medicus Pharma’s skin cancer program showed more than 60% clinical clearance in the first 26 randomized...
Precision Medicine Update: China Study & FDA Resubmissions
Telix reported a 94.8% overall patient-level PPV (95% CI: 85.9%–98.2%) in its 140-patient Phase 3 registration study of TLX591-CDx...
BPGbio Publishes Pioneering AI-Guided Solid Tumor Study
Phase 1a/1b data in 97 patients with advanced solid tumors showed that intravenous BPM31510, a mitochondrial metabolic modulator, induced...
Kalaris Reports Promising Phase 1a Data for AMD Drug
Kalaris reported initial Phase 1a data for TH103 in treatment-naïve nAMD showing a mean 10-letter BCVA gain at Month...